Analyzing CRISPR Therapeutics’ Q4 And Full-Year 2017 Results – Seeking Alpha
Investorplace.com |
Analyzing CRISPR Therapeutics' Q4 And Full-Year 2017 Results
Seeking Alpha For the fourth quarter 2017, CRISPR reported diluted earnings per share of $0.00 which beat EPS forecasts by $0.77; however, this is down from $0.40 per share in the fourth quarter of 2016. Full-year 2017 Diluted EPS was $(1.71), and improvement over … Does Crispr Therapeutics AG Deserve This Massive Rally? Crispr Therapeutics AG (CRSP) Receives Consensus Recommendation of “Buy” from Brokerages Headcount soars at Cambridge gene editing biotechs as trials near |
